Arcturus Therapeutics (NASDAQ: ARCT) reported Q3 EPS of ($0.26), $0.31 better than the analyst estimate of ($0.57). Revenue for the quarter came in at $41.67 million versus the consensus estimate of $53.46 million.

For earnings history and earnings-related data on Arcturus Therapeutics (ARCT) click here.